TABLE 2.
Summary of Treatment, Patient Outcome and Follow-Up Results
| PED size | Periprocedural | mRS | Angiography | mRS | Angiography | mRS | Angiography | mRS | |
|---|---|---|---|---|---|---|---|---|---|
| Pt# | [mm]/version | complication | discharge | follow-up 1 mo | 1 mo | follow-up at 6 mo | 6 mo | follow-up 12 mo | 12 mo |
| 1 | 2.5 × 16 Flex | None | 0 | – | – | Complete occlusion, patent PED, no IH | 0 | – | – |
| 2 | 2.5 × 12 Classic | None | 0 | – | – | Not available | – | Complete occlusion, patent PED, no IH | 0 |
| 3 | 2.5 × 12 Flex | None | 0 | – | – | Persistent filling with 60% aneurysmal sac volume reduction, patent PED, no IH | 0 | Persistent filling with 65% aneurysmal sac volume reduction, patent PED, no IH | – |
| 4 | 2.5 × 12 Classic | None | 0 | – | – | Complete occlusion, patent PED, minimal IH | 0 | – | – |
| 5 | 2.5 × 10 Classic | None | 0 | – | – | Complete occlusion, patent PED, no IH | 0 | Complete occlusion, patent PED, no IH | 0 |
| 6 | 2.5 × 20 Classic | None | 0 | Persistent filling with 90% aneurysmal sac volume reduction, patent PED, no IH | 0 | Complete occlusion, patent PED, no IH | 0 | – | – |
| 7 | 2.5 × 16 Classic | None | 0 | Persistent filling with 60% aneurysmal sac volume reduction, patent PED, no IH | 0a | Persistent filling with 96% aneurysmal sac reduction, patent PED, no IH | 0 | – | – |
Pt# = patient number, PED = pipeline embolization device, IH = intimal hyperplasia, mRS = modified Rankin score.
aThere was a transient change to mRS 1 related to a second procedure. However, the patient returned to baseline after a few weeks.